What Stelara Treats: Main Uses and Benefits

Stelara (ustekinumab) is generally applied in clinical settings that involve chronic, inflammatory, and unstable symptom patterns related to autoimmune conditions. It is used for the management of: moderate to severe plaque psoriasis, active psoriatic arthritis, and moderately to severely active Crohn's disease and ulcerative colitis.

This treatment is primarily relevant for easing symptoms that interfere with daily functioning, such as persistent skin plaques, painful swollen joints, and disruptive digestive issues. It supports patients during difficult episodes by easing distress and assists with maintaining functional stability.

“It provides support that helps ease the overall symptom burden, which may help improve day-to-day comfort during symptomatic periods.”

By managing these symptoms, Stelara may help patients cope more steadily with symptom fluctuations across these conditions.

---

Quick Fact: Relief for Chronic Inflammation Stelara is used for conditions marked by underlying chronic inflammation, such as Psoriasis, Psoriatic Arthritis, and Inflammatory Bowel Disease. It is relevant for easing symptoms related to inflammatory or irritative states.

Official Population Eligibility for Stelara

The ability to use Stelara is strictly defined by regulatory criteria regarding age, health status, and other patient characteristics.

Contraindicated Populations

Use is contraindicated (must not be used) in any patient with a known clinically significant hypersensitivity to ustekinumab or its excipients. It is also contraindicated for patients who have a clinically important, active infection, including active tuberculosis.

Age-Related Eligibility

Stelara is approved for adults across all labeled conditions. Pediatric eligibility begins at 6 years of age and older for Plaque Psoriasis and Psoriatic Arthritis. For Crohn's Disease, approval includes pediatric patients who weigh at least 40 kg. Use is generally not recommended for children under six years of age.

Conditional Use and Limitations

Regulatory rules require patients to be screened for latent tuberculosis infection, with treatment initiated prior to starting Stelara if necessary. Caution is advised for use in patients with a history of malignancy. For those with renal or hepatic impairment, use is not studied, and no dose recommendations can be made. Women of childbearing potential must use effective contraception during therapy and for 15 weeks following the last dose.

The interaction profile for ustekinumab (Stelara) is primarily defined by the requirement to manage concurrent immune-modifying substances, as documented by government regulatory authorities.

Immunologic Co-administration Restrictions

• The co-administration of live viral or live bacterial vaccines is prohibited during therapy. This restriction is based on the immunosuppressive nature of ustekinumab.
• A mandatory timing rule requires ustekinumab treatment to be withheld for at least 15 weeks prior to a live vaccination and can only be resumed at least 2 weeks after the vaccination.
• For infants with in utero exposure to the drug, live vaccines are not recommended for twelve months following birth or until infant drug levels are undetectable.
• The safety and efficacy of combining ustekinumab with other biologic immunosuppressants or phototherapy have not been evaluated in psoriasis studies, warranting a formal caution based on the absence of data.

Pharmacokinetic and Metabolic Interactions

Regulatory studies have shown that ustekinumab has no clinically significant effect on the activity of the major human CYP450 isoenzymes (e.g., 1A2, 2C9, 2C19, 2D6, 3A). This finding prevents the need for formal pharmacokinetic interaction warnings regarding altered clearance of co-administered CYP substrates.

Similarly, the use of traditional immunomodulators (e.g., methotrexate, azathioprine, 6-mercaptopurine) in combination with ustekinumab did not appear to influence overall safety or efficacy in clinical trials.

Targeted Blockade of Key Inflammatory Signals (IL-12 and IL-23)

Stelara (Ustekinumab) is a monoclonal antibody that acts as a cytokine antagonist, binding specifically to the p40 protein subunit shared by Interleukin-12 (IL-12) and Interleukin-23 (IL-23). This targeted blockade prevents these two inflammatory messengers from activating the IL-12Rbeta 1 receptor on immune cells.

---

Suppression of the Th1 and Th17 Immune Pathways

The molecular blockade initiates a mechanistic cascade that modulates key pathways associated with immune responses, specifically the T helper 1 ( Th1) and T helper 17 ( Th17) cell lines. By cutting off the signaling required for their activation and survival, the mechanism leads to a decrease in the downstream release of pro-inflammatory cytokines ( IFN-gamma , IL-17, IL-22).

---

Resulting Physiological Regulation

Engaging mechanisms that regulate overactive inflammatory processes alters the cytokine profile within targeted immune pathways. The physiological consequence of this targeted interference is the modulation of immune cell migration into tissues and the reduction of the inflammatory cascade. This adjustment reflects the drug's action on the underlying biological process.

How to Use Stelara (Ustekinumab): Official Administration Guidelines

Stelara is administered following a strict, two-phase treatment schedule that involves an initial induction period and a long-term maintenance phase. The required route of administration, dosage amount, and frequency are dictated by the specific condition being treated.

---

Administration Routes and Scheduling

Stelara is administered via Subcutaneous (SC) injection or as a single, initial Intravenous (IV) infusion.

Condition	Induction Schedule	Maintenance Schedule & Route
Psoriasis/Psoriatic Arthritis (Adults)	SC injection at Week 0 and Week 4	SC injection every 12 weeks
Crohn’s Disease/Ulcerative Colitis (Adults)	Single weight-based IV infusion	SC injection every 8 weeks

---

Dosage and Procedural Rules

Dosages are highly specific and may be adjusted based on body weight. For adults with Psoriasis or Psoriatic Arthritis, patients weighing leq 100 kg typically receive a 45 mg dose, while those weighing > 100 kg typically receive a 90 mg dose for both induction and maintenance.

For Crohn’s Disease and Ulcerative Colitis in adults, the single IV induction dose is weight-based (e.g., 260 mg, 390 mg, or 520 mg) and must be administered by a healthcare professional over at least one hour. This IV induction is followed by a 90 mg SC maintenance dose starting 8 weeks later, and then every 8 weeks thereafter.

Pediatric patients (6 years) with Psoriasis or Psoriatic Arthritis receive weight-based SC dosing at Week 0, Week 4, and then every 12 weeks. For SC injection, the pre-filled syringe should be visually inspected and allowed to warm to room temperature for about 30 minutes before use, and the injection sites must be rotated.

Research evidence / Overview of Studies for Stelara (Ustekinumab)

---

Evidence for Use in Plaque Psoriasis

The clinical evaluation for moderate to severe chronic plaque psoriasis is based on Phase 3 randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time, comparing treatment against an inactive substance (placebo). Long-term extension studies were also used in observational settings evaluating patient-reported experiences over multiple years.

The main goal of these studies was to evaluate proportional changes in the Psoriasis Area and Severity Index (PASI). Research was conducted to examine outcomes related to physical discomfort and daily functioning. Findings described patterns observed in the trials, with reports summarizing the percentage of patients who met these clearance endpoints during the initial treatment phases. Few dedicated studies have been conducted for the geriatric population (aged 65 years and older).

---

Evidence for Use in Psoriatic Arthritis

The research for active Psoriatic Arthritis (PsA) includes two Phase 3 Randomized Controlled Trial (RCT) programs. Studies monitored outcomes related to functional imbalance and activity level, primarily using the ACR 20 response criteria. Study reports described the proportion of patients who reached the threshold of ACR 20 criteria, and patterns related to these outcomes were assessed through the one-year mark. Data for PsA in pediatric populations are insufficient.

---

Evidence for Use in Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)

Crohn's Disease Research Structure

Studies for Crohn's Disease evaluated both initial response and maintenance. Research also examined endoscopic improvement, which assesses the visible state of the intestinal lining. Long-term extension data describe patterns observed in patients continuing treatment over approximately five years. Data for certain small, weight-defined pediatric groups remain insufficient.

Ulcerative Colitis Research Structure

Studies for Ulcerative Colitis (UC) examined symptom intensity and variability, primarily using the Mayo score for assessing clinical remission. Evidence explored outcomes capturing cellular level changes in the colon lining (HEMI). Data for the pediatric population (under 18 years) are still emerging.

---

Key Evidence Gaps and Areas of Uncertainty

Key limitations include limited direct head-to-head randomized trials comparing Stelara against every newer biologic agent available. The sequencing of treatment and criteria for changing the treatment regimen in patients who experience a waning response are areas where research is ongoing.

Common questions about Stelara (FAQ)

Q: Does Stelara treat all forms of psoriasis, or only plaque psoriasis?

A: Stelara is officially approved for the treatment of moderate to severe plaque psoriasis, as specified in regulatory documents. It is also approved for the treatment of psoriatic arthritis. Official information limits the approved conditions to those studied and included in the prescribing information.

Q: How is the infusion different from the subcutaneous injection?

A: The main difference is the route and setting of administration. The initial dose for Crohn's disease and ulcerative colitis is given as an intravenous (IV) infusion, administered by a healthcare professional. The subcutaneous (SC) injection is the route used for maintenance dosing in these conditions, and all doses for psoriasis.

Q: Is Stelara used for conditions other than inflammatory bowel disease or psoriasis?

A: Official documents confirm that Stelara is indicated for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. These are the conditions for which regulatory bodies have granted approval. The prescribing information does not list additional indications.

Q: Can Stelara be used in children, and if so, for which conditions?

A: Regulatory documents state that Stelara is approved for the treatment of plaque psoriasis and psoriatic arthritis in children 6 years of age and older. The safety and effectiveness of the drug for Crohn’s disease or ulcerative colitis have not been established in children younger than 18.

Q: What are the primary components of the Stelara injection/infusion?

A: The primary component is the active substance, ustekinumab, a type of monoclonal antibody. The product also contains inactive ingredients, or excipients, which are listed in the official prescribing information. Additionally, the needle cover of the pre-filled syringe contains dry natural rubber, which is a form of latex.

Q: What is the mechanism of action of Stelara in simple terms?

A: Stelara works by targeting and attaching to two specific protein messenger molecules in the immune system, Interleukin-12 (IL-12) and Interleukin-23 (IL-23). By blocking these messengers, the drug helps to regulate the immune system responses that cause inflammatory conditions.

Q: Can Stelara cause hair loss?

A: Hair loss is not typically listed among the most frequently reported side effects in clinical trials summarized in regulatory documents. Official product information contains a comprehensive list of all reported side effects, which may include uncommon or rare occurrences.

Q: Are there any common foods or supplements that interact with Stelara?

A: Official guidance on interactions indicates that information about all medicines taken, including over-the-counter medicines, vitamins, and herbal supplements, should be provided to a healthcare professional. There is no specific official information or warning highlighting common food interactions.

Q: What happens if a person misses a dose of Stelara?

A: Regulatory documents state that a double dose is not indicated to compensate for a missed dose. Official guidance specifies that the next step regarding a missed dose is determined by the healthcare professional.

Q: Is it true that Stelara makes you more susceptible to infections?

A: As a selective immunosuppressant, regulatory documents confirm that Stelara may increase the risk of infections by lowering the body’s ability to fight them. Serious infections have been observed in some patients receiving this treatment.

Q: Can Stelara be used by people who are also taking methotrexate?

A: According to regulatory documents, the use of methotrexate (MTX) in combination with Stelara did not appear to impact the safety or efficacy profile of the drug in studies for certain conditions, such as psoriatic arthritis.

Q: Do people typically experience fatigue after taking Stelara?

A: Tiredness or fatigue is listed as a common side effect in the official prescribing information for Stelara.

Q: What are the most common side effects listed for Stelara?

A: Common side effects reported in clinical trials and listed in official documents include upper respiratory infections, nasopharyngitis, fever, headache, and fatigue.

Q: Is Stelara safe for people with a history of cancer?

A: Regulatory documents advise that Stelara has the potential to increase the risk for certain types of cancer. Official guidance indicates that caution is necessary when its use is considered for patients with a history of malignancy, and the prescribing information notes that monitoring for the appearance of skin cancer is included in the treatment protocol.

Q: Can I drink alcohol while I am on Stelara?

A: The official product documentation indicates that there is no specific information available regarding the effects of combining Stelara with alcohol.

Q: Is there a link between Stelara and feeling depressed or anxious?

A: Official product information lists depression as an uncommon side effect of Stelara.

Q: Does Stelara contain latex or any common allergens?

A: The needle cover on the pre-filled syringe is noted to contain dry natural rubber, which is a form of latex. A known hypersensitivity to the active substance (ustekinumab) or any of the product's inactive ingredients is a contraindication.

Q: Do patients need special monitoring while taking Stelara?

A: Yes, official treatment protocols include close monitoring for signs of infection, as well as for the appearance of skin cancer and the recurrence of tuberculosis (TB), during and after treatment.

Q: What should be done if a patient gets a fever while using Stelara?

A: Official guidance states that symptoms suggestive of an infection, such as fever, sweats, or chills, are conditions for which immediate medical attention is specified.

Q: Is it normal to have a small reaction at the injection site?

A: Yes, a small reaction at the injection site, such as redness, pain, or swelling, is listed as a common side effect in official documents.

Q: Will Stelara affect my ability to get certain types of vaccines?

A: Regulatory information states that live viral or live bacterial vaccines are not recommended while undergoing treatment with Stelara. Furthermore, official guidance indicates that information about any household member needing a live vaccine should be provided to a healthcare professional.

Q: Are there any specific blood tests needed before starting Stelara?

A: Regulatory requirements for starting a biologic often involve screening for severe infections such as tuberculosis (TB), which may require blood tests or other diagnostic evaluations before treatment can begin.

Q: What are the typical conditions that prevent someone from using Stelara?

A: Stelara is contraindicated for people with a known hypersensitivity to any of its ingredients. It is also contraindicated for people who have a clinically important, active infection, such as active tuberculosis.

Q: What kind of research has been done on the safety of Stelara during pregnancy?

A: Official documents state that it is not known if Stelara can harm an unborn baby as human data is limited. Regulatory guidance specifies that infants exposed to the product may require an altered schedule for live vaccines, as the product is expected to cross the placenta in the later stages of pregnancy.

Q: Does Stelara need to be kept refrigerated all the time?

A: Regulatory guidance specifies that Stelara storage requires refrigeration between 2 C and 8 C and protection from light. However, the pre-filled syringe may be maintained at room temperature (up to 30 C) for a single period of up to 30 days, after which disposal is required if the product is not used.

Q: Is there a risk of developing a new medical condition while on Stelara?

A: Regulatory documents report cases of rare, serious conditions that have been observed in some patients receiving Stelara, including Posterior Reversible Encephalopathy Syndrome (PRES) and certain types of lung inflammation.

Q: Do older adults react differently to Stelara than younger adults?

A: Regulatory information highlights that the official monitoring protocol is heightened for patients older than 60 years of age, particularly those with a history of long-term immunosuppressant therapy, to check for the appearance of skin cancer.

Q: Can I take over-the-counter pain relievers like ibuprofen while on Stelara?

A: Official guidance indicates that information about all medicines being taken, including over-the-counter pain relievers, should be provided to a healthcare professional to review for potential interactions.

Q: Are there any known interactions with herbal remedies or multivitamins?

A: Official documents indicate that information about all substances being used, including vitamins, herbal remedies, and other supplements, should be provided to a healthcare professional.

Q: Is it normal to feel a bit sick or flu-like after the first Stelara injection?

A: Flu-like symptoms, fever, and fatigue are listed among the common side effects of Stelara in official prescribing information.

Q: What criteria do official bodies use to assess who is eligible for Stelara?

A: Eligibility is assessed based on the official indications for the drug (such as the specific condition, disease severity, and age) and the absence of contraindications (such as active infection or hypersensitivity).

Q: How is the safety profile of Stelara described in official documents?

A: The safety profile includes common side effects, warnings about the potential for serious infections and malignancies, and information on rare serious conditions like Posterior Reversible Encephalopathy Syndrome (PRES) and lung inflammation.

Q: What are the contraindications listed for Stelara?

A: Official documents list two primary contraindications: a known hypersensitivity to ustekinumab or any of its ingredients, and the presence of a clinically important, active infection, such as active tuberculosis.

Q: Is Stelara known to cause changes in skin texture or appearance?

A: Official documents list various skin-related side effects, including itching, acne, pustular psoriasis, and skin exfoliation. Rare cases of lupus-related conditions have also been reported.

Q: Do regulatory bodies classify Stelara as having a high risk of serious infection?

A: Regulatory documentation states that Stelara may lower the body's ability to fight infections and may increase the risk of serious infections. Official labels include warnings about the serious infections that have been observed in some patients.

Q: Does Stelara have a boxed warning in official documents?

A: The U.S. Prescribing Information contains a Boxed Warning regarding the potential for serious infections and the observed occurrence of malignancies (cancers) in some patients.

Storage and Stability Requirements

Stelara (ustekinumab) must be stored in the refrigerator between 2 C to 8 C (36 F to 46 F). To protect it from light, the product must be kept in its original carton until the time of use. It is strictly required not to freeze or shake the medicine; if freezing occurs, the product must be discarded.

Room Temperature Allowance

If necessary, individual pre-filled syringes can be stored outside the refrigerator at room temperature, up to 30 C (86 F), for a single maximum period of up to 30 days. If this room temperature allowance is used, the date of removal from the refrigerator must be noted on the carton, and the syringe must not be returned to refrigeration. It must be discarded if not used within the 30-day period.

Handling and Disposal

Before use, the medicine should be visually inspected; it must not be used if it is discolored, cloudy, or contains particulate matter. Since Stelara is a single-use product, any unused portion must be discarded. All used needles, syringes, or vials must be immediately placed in an FDA-cleared, puncture-proof sharps disposal container and kept out of the reach of children. The full sharps container must be disposed of according to local regulatory guidelines for hazardous waste.